Abbott to Acquire Exact Sciences
Abbott to Acquire Exact Sciences expands Abbott's diagnostics base and forces reassessment of positioning as accretion, deal size and timing are priced.
KEY TAKEAWAYS
- Exact Sciences shareholders to receive $105 per share cash; deal values equity near $21.0B and EV about $23.0B.
- Abbott said the acquisition will be immediately accretive to revenue growth and gross margin.
- Transaction expected to close in Q2 2026 pending shareholder and regulatory approvals.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Abbott Laboratories announced a definitive agreement on Nov. 20, 2025, to acquire Exact Sciences, the cancer-test maker, expanding Abbott’s diagnostics footprint and reshaping its near-term growth profile.
Exact Sciences Acquisition Terms and Strategic Impact
Abbott (NYSE: ABT) and Exact Sciences (NASDAQ: EXAS) agreed that Exact Sciences shareholders will receive $105 per share in cash, valuing the equity at about $21 billion and the enterprise at roughly $23 billion, including $1.8 billion of net debt. Both boards unanimously approved the transaction. Morgan Stanley advised Abbott, while Centerview Partners and XMS Capital Partners advised Exact Sciences.
The deal is expected to close in the second quarter of 2026, pending shareholder and regulatory approvals and customary closing conditions. The companies scheduled an investor call for 9:00 a.m. ET.
Abbott said the acquisition will be immediately accretive to revenue growth and gross margin. It adds a new growth vertical by expanding Abbott’s presence in the U.S. cancer screening and precision oncology diagnostics market, estimated at $60 billion annually.
Exact Sciences projects 2025 revenue above $3 billion with a high-teens organic sales growth rate. After closing, Abbott’s diagnostics segment is expected to exceed $12 billion in annual sales. Exact Sciences will become a subsidiary headquartered in Madison, Wisconsin, with CEO Kevin Conroy serving in an advisory role during the transition. Exact’s product portfolio includes Cologuard, Oncotype DX, Cancerguard, Oncodetect, and OncoExTra.
